LGALS9C

Across TCGA pan-cancer cohorts, LGALS9C RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated LGALS9C data layer compared with 2 for mutation status.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LGALS9C RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LGALS9C expression acts as an unfavorable survival marker, although some lineages such as CESC and READ show a favorable association.

CHOL, CESC, and UCEC are the cancer types where LGALS9C RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Quartile	II,III,IV	0.171	0.901	.001	54	view →
CESC	OS	Median	All	0.867	0.723	<.001	44	view →
UCEC	DFS	Quartile	All	0.456	0.784	.006	44	view →
LUAD	DFS	Tertile	III,IV	0.245	0.514	.004	40	view →
LGG	OS	Tertile	All	0.310	0.496	<.001	35	view →
READ	DFS	Median	III,IV	0.930	0.317	.004	34	view →
COAD	DFS	Median	IV	0.464	0.204	.004	14	view →
KIRP	OS	Median	IV	0.047	0.520	.032	12	view →
LIHC	OS	Median	III,IV	0.397	0.620	.007	9	view →
UVM	DFS	Median	III,IV	0.843	0.194	.023	8	view →
TGCT	DFS	Quartile	All	0.878	0.563	.009	8	view →
MESO	OS	Median	III,IV	0.333	0.685	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

LGALS9C–CHOL (OS)

Open the CHOL breakdown →